Review article: treatments that impact favourably upon the eradication of Helicobacter pylori and ulcer recurrence

Alimentary Pharmacology & Therapeutics

Volumn 8, Issue 4, 1994, Pages 359-368

  TYTGAT, G N J ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; BISMUTH CITRATE; BISMUTH SALICYLATE; CLARITHROMYCIN; CLAVULANIC ACID; LANSOPRAZOLE; METRONIDAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR; RANITIDINE; TETRACYCLINE; TINIDAZOLE;

ANTIBIOTIC THERAPY; CANDIDIASIS; DIARRHEA; DRUG MIXTURE; GASTRODUODENAL ULCER; GRAM NEGATIVE INFECTION; HELICOBACTER PYLORI; HUMAN; PSEUDOMEMBRANOUS COLITIS; RECURRENT DISEASE; RECURRENT PEPTIC ULCER; REVIEW;

ANTIBIOTICS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMAN; HYDROGEN-ION CONCENTRATION; MICROBIAL SENSITIVITY TESTS; OMEPRAZOLE; PEPTIC ULCER; RECURRENCE;

EID: 0027968850     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.1994.tb00303.x     Document Type: Article

References (123)

1. Simple noninvasive method to test efficacy of drugs in the eradication of Helicobacler pufori infection : the example of combined bismuth subsalicylate and nitrofurantoin
2. Effect of ranitidine and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer
3. Meta‐analysis of the efficacy of antibiotic therapy in eradicating Helicobacter pylori
4. Role of Campylobacter pyloridis in non‐ulcer dyspepsia
5. Inhibitory antimicrobial concentrations against Campylobacter pylori in gastric mucosa
6. Amoxycillin concentration in antrum, corpus and fundus of the stomach after single oral application
7. Secretion of intravenously administered antibiotics in gastric juice: Implications for management of Helicobacter pylori
8. Gastric secretion of antibiotics used for Campylobacter pyloridis
9. Penicillin‐binding proteins and the mechanism of action of beta‐lactam antibiotics
10. Assessment of Helicobacter pylori's sensitivity to tinidazole, amoxycillin and tetracycline among 472 patients
11. Galenical formulations of amoxicillin/clavulanate and eradication of Helicobacter pylori in peptic ulcer patients: preliminary report
12. Hepatitis associated with amoxycillin‐clavulanic acid combination
13. In vitro sensitivity of Helicobacter pylori
14. Effect of varying pH on the susceptibility of Campylobacter pylori to antimicrobial agents
15. Proposed mechanism for metronidazole resistance in Helicobacter pylori
16. Bismuth pharmacokinetics in the human gastric mucosa
17. In vitro bactericidal effects of CBS on Helicobacter pylori
18. Colloidal bismuth subcitrate (CBS) blocks Helicobacter pylori adhesion to glycero‐lipid receptors
19. Pharmacology of bismuth containing medicines used to treat Helicobacter pylori infections
20. Trans‐mucosal penetration of bismuth particles in the human stomach
21. Antibacterial agents. Macrolides
22. The role of antibiotics in Campylobacter pylori associated Peptic Ulcer Disease
23. Antibacterial Agents. Tetracyclines
24. Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori
25. Activity of lansoprazole against Helicobacter pylori
26. Antibacterial activity of pantoprazole and omeprazole against Helicobacter pylori
27. Inhibition of Helicobacter pylori urease by omeprazole
28. High dose omeprazole treatment combined with amoxicillin eradicates Helicobacter pylori
29. No effects of omeprazole‐induced hypoacidity on the bioavailability of amoxycillin or bacampicillin
30. Bacteriological and pharmacological basis for the treatment of Campylobacter pylori infection
31. Campylobacter pyloridis and acid induced gastric metaplasia in the pathogenesis of duodenitis
32. Effect of treatment of Helicobacter pylori infection on the long‐term recurrence of gastric or duodenal ulcer
33. Patient factors affecting Helicobacter pylori eradication with triple therapy
34. Amoxicillin added to omeprazole prevents relapse in the treatment of duodenal ulcer patients
35. Short report: smoking habits and the acquisition of metronidazole resistance in patients with Helicobacter pylori‐related gastritis
36. Experience with ‘triple’anti‐Helicobacter pylori eradication therapy: side effects and the importance of testing the pre‐trcatment bacterial isolate for metronidazole resistance
37. Recurrence of duodenal ulcer and Campylobacter pylori infection after eradication
38. Helicobacter pylori eradication with doxycyclin‐metronidazole‐bismuth subcitrate triple therapy
39. Cure of duodenal ulcer after eradication of Helicobacter pylori
40. Successful eradication of H. pylori infection prevents recurrence of duodenal ulceration
41. Short report: short‐term triple therapy for H
42. Clinical efficacy of triple therapy in Helicobacter pylori‐associated duodenal ulcer
43. Long‐term follow‐up and antibody response to treatment of patients with Helicobacter pylori
44. Effect of treatment of Helicobacter pylori infection on the long‐term recurrence of gastric or duodenal ulcer
45. High efficacy, low dose triple therapy (TT) for Helicobacter pylori (HP)
46. Relevance of in vitro metronidazole resistance to H. pylori (HP) eradication and eradication failure
47. Failure to eradicate Helicobacter pylori in patients with metronidazole‐resistant strains
48. Efficiency of oral triple therapy (BSS/metronidazole/tetracycline) to eradicate HP in DU disease
49. Spontaneous healing of duodenal ulcers after eradication of H
50. Experience with ‘triple’ anti‐HWicobacterpy/ori eradication therapy: side‐effects and the importance of testing the pre‐treatment bacterial isolate for metronidazole resistance
51. Triple therapy after duodenal ulcer healing with omeprazole or ranitidine eradicates H. pylori and prevents ulcer relapses: preliminary results of a year follow up study
52. Two‐week combination therapies with tetracycline are less effective than similar regimens with amoxicillin
53. Optimising therapy for H
54. Duodenal ulcers heal without acid suppression if Helicobacter pylori is eradicated–a randomized trial
55. Campylobacter pyloridis‐associated chronic active antral gastritis
56. Plasma gastrin, daytime intragastric pH and nocturnal acid output before and at 1 and 7 months after eradication of Helicobacter pylori in duodenal ulcer subjects
57. What treatment is best for gastric Helicobacter pylori infection
58. The role of omeprazole in the treatment of gastric Helicobacter pylori infection
59. Evaluation of various multidrug eradication regimens for Helicobacter pylori
60. Role of metronidazole resistance in therapy of Helicobacter pylori infections
61. Short‐ and medium‐term results of oral triple therapy to eradicate C. pylori
62. Comparison of two therapeutic schedules for the treatment of Helicobacter pylori infection
63. Helicobacter pylori therapy randomized study of denol/antibiotic combinations
64. One week eradication regimen for Helicobacter pylori
65. Helicobacter pylori positive dyspepsia: results of four days treatment
66. Triple therapy of Helicobacter pylori infection in peptic ulcer
67. Decrease in Gastrin. Pepsinogen A and C basal serum levels after oral triple therapy (OTT): A marker for Helicobacter pylori eradication
68. Eradication of Helicobacter pylori and duodenal ulcer relapse
69. Modified combined omeprazole/amoxicillin therapy regimen for eradication of H. pylori–a pilot study
70. Zweiwöchige Amoxycillin/Omeprazole‐Therapie zur Helicobacter pylori‐Eradication
71. High dose omeprazole treatment combined with amoxicillin eradicates Helicobacter pylori
72. Does omeprazole improve antimicrobial therapy directed towards gastric Campylobacter in patients with antral gastritis
73. Omeprazole improves amoxicillin therapy towards Helicobacter pylori associated chronic gastritis
74. Amoxycillin‐omeprazole treatment for eradication of Helicobacter pylori
75. Experience with omeprazole in combination with either amoxycillin or colloidal bismuth subcitrate in patients with metronidazole resistant Helicobacter pylori
76. A treatment regimen for metronidazole resistant Helicobacter pylori (MRHP)
77. Omeprazole and amoxycillin suspension for Helicobacter pylori
78. Pretreatment with omeprazole endangers the efficiency of amoxicillin/omeprazole treatment to eradicate HP
79. Omeprazole and amoxicillin in patients with duodenal ulcer: Helicobacter pylori eradication and remission of ulcers and symptoms during a 6 month follow‐up
80. Short Report: Omeprazole + antibiotic combinations for the eradication of metronidazole‐resistant Helicobacter pylori
81. High dose omeprazole plus amoxycillin in the treatment of acute duodenal ulcer
82. Clarithromycin and omeprazole for Helicobacter pylori
83. Helicobacter pylori (HP) eradication and sequential clearance of inflammation in duodenal ulcer patients treated with omeprazole and antibiotics
84. Controlled study of omeprazole‐amoxicillin‐tinidazole vs ranitidine‐amoxicillin‐tinidazole in Helicobacter pylori associated duodenal ulcers (DU)
85. Efficacy and tolerability of a short term low dose
86. Personal communication
87. Campylobacter pylori and recurrence of duodenal ulcers: a 12‐month follow‐up study
88. Effect of colloidal bismuth (DeNol) on healing and relapse of duodenal ulcers: role of Campylobacter pylohdis
89. Prospective double blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori
90. A comparison of ranitidine and tripotassium dicitratobismuthate (TDB) in relapse rates of duodenal ulcer: the role of Campylobacter pylori (C.p.)
91. Long‐term Campylobacter pylori recurrence posteradication
92. Eradication of Helicobacter pylori cures duodenal ulcer disease
93. The effect of Helicobacter pylori on the healing and relapse of duodenal ulcer
94. De‐Nol plus oxacillin vs ranitidine and oxacillin in Up‐positive duodenal ulcers: Effects on relapse
95. prospective study ofHelicobacter pylori eradication in duodenal ulcer
96. Helicobacter pylori eradication prevents duodenal ulcer relapse
97. Effects of triple therapy (antibiotics plus bismuth) on duodenal ulcer healing
98. Long‐term evaluation of anti‐Helicobacter pylori treatment in duodenal ulcer (DU)
99. Relationship between Helicobacter pylori recurrence and relapse of duodenal ulcer
100. Duodenal ulcer relapse after eradication of Helicobacter pylori
101. Eradication of H. pylori prevents duodenal ulcer recurrence
102. Duodenal ulcer and eradication ofHelicobacter pylori in a developing country
103. Hp reinfection and clinical course of ulcer disease in the first year after amoxicillin/omeprazole treatment
104. Decreased relapse rate after antibacterial treatment of Helicobacter pylori‐associated duodenal ulcers
105. One year relapse rate after H. pylori eradication with omeprazole plus antimicrobials
106. One week therapy for Helicobacter pylori eradication: Follow‐up study of a randomized trial at one year after treatment
107. Prospective, randomized investigator‐blind trial of Helicobacter pylori infection treatment in patients with refractory duodenal ulcers
108. Treatment of Helicobacter pylori‐associated duodenal ulcer with omeprazole plus antibiotics
109. Reduction of gastric ulcer recurrence after suppression of Helicobacter pylori by ceftrixime
110. In the Finnish gastric ulcer study group (FGUSG)
111. Antibacterial treatment of gastric ulcers–German Gastric Ulcer Study